Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4636)
All Articles published online
|
Publishing Process of This Article
|
Dec 27, 2020 (publication date) through May 13, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Shafiq M, Walmann T, Nutalapati V, Gibson C, Zafar Y. Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver. World J Hepatol 2020; 12(12): 1258-1167 [PMID: 33442452 DOI: 10.4254/wjh.v12.i12.1258] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v12/i12/1258.htm |
| Number | Citing Articles |
| 1 |
Daqing Zhang, Zhen Mi, Jiya Peng, Tiangui Yang, Yuze Han, Yujia Zhai, Chenliang Song, Xianzhuo Teng, Wei Sun, Jing Guo, Kabeya Paulin Bilonda. Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases. Journal of Cardiovascular Pharmacology 2023; 81(5): 327 doi: 10.1097/FJC.0000000000001418
|
| 2 |
Paolo Raggi, Jovana Milic, Marcella Manicardi, Felice Cinque, Mark G. Swain, Giada Sebastiani, Giovanni Guaraldi. Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology. Atherosclerosis 2024; 392: 117523 doi: 10.1016/j.atherosclerosis.2024.117523
|
| 3 |
Meng Yang, Chang-An Geng, Xinguang Liu, Min Guan. Lipid Disorders in NAFLD and Chronic Kidney Disease. Biomedicines 2021; 9(10): 1405 doi: 10.3390/biomedicines9101405
|
| 4 |
Mateusz Maligłówka, Michał Kosowski, Marcin Hachuła, Marcin Cyrnek, Łukasz Bułdak, Marcin Basiak, Aleksandra Bołdys, Grzegorz Machnik, Rafał Jakub Bułdak, Bogusław Okopień. Insight into the Evolving Role of PCSK9. Metabolites 2022; 12(3): 256 doi: 10.3390/metabo12030256
|
| 5 |
Lizhu Han, Liuyun Wu, Qinan Yin, Lian Li, Xingyue Zheng, Shan Du, Xuefei Huang, Lan Bai, Yi Wang, Yuan Bian. A promising therapy for fatty liver disease: PCSK9 inhibitors. Phytomedicine 2024; 128: 155505 doi: 10.1016/j.phymed.2024.155505
|
| 6 |
Veronika A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines 2022; 10(2): 274 doi: 10.3390/biomedicines10020274
|
| 7 |
Thomas Grewal, Christa Buechler. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond. International Journal of Molecular Sciences 2022; 23(3): 1070 doi: 10.3390/ijms23031070
|
| 8 |
Ismini Tzanaki, Aris P Agouridis, Michael S Kostapanos. Is there a role of lipid-lowering therapies in the management of fatty liver disease?. World Journal of Hepatology 2022; 14(1): 119-139 doi: 10.4254/wjh.v14.i1.119
|
| 9 |
Rosaria Vincenza Giglio, Emir M. Muzurović, Angelo Maria Patti, Peter P. Toth, Manyoo A. Agarwal, Wael Almahmeed, Aleksandra Klisic, Marcello Ciaccio, Manfredi Rizzo. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?. Journal of Cardiovascular Pharmacology and Therapeutics 2023; 28 doi: 10.1177/10742484231186855
|
| 10 |
Liuxin Ning, Yanting Zou, Shuyu Li, Yue Cao, Beili Xu, Shuncai Zhang, Yu Cai. Anti-PCSK9 Treatment Attenuates Liver Fibrosis via Inhibiting Hypoxia-Induced Autophagy in Hepatocytes. Inflammation 2023; 46(6): 2102 doi: 10.1007/s10753-023-01865-8
|
| 11 |
Majambu Mbikay, Michel Chrétien. The biological relevance of PCSK9: when less is better…. Biochemistry and Cell Biology 2022; 100(3): 189 doi: 10.1139/bcb-2021-0540
|
| 12 |
Xiang Gao, Ling Yi, Chang Jiang, Shuping Li, Xiaojue Wang, Bin Yang, Weiying Li, Nanying Che, Jinghui Wang, Hongtao Zhang, Shucai Zhang. PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1142428
|
| 13 |
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień. Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease. Medicina 2023; 59(10): 1789 doi: 10.3390/medicina59101789
|
| 14 |
Xuhui Bao, Yongjun Liang, Hanman Chang, Tianji Cai, Baijie Feng, Konstantin Gordon, Yuekun Zhu, Hailian Shi, Yundong He, Liyi Xie. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. Signal Transduction and Targeted Therapy 2024; 9(1) doi: 10.1038/s41392-023-01690-3
|
| 15 |
Amir Abbas Momtazi-Borojeni, Maciej Banach, Massimiliano Ruscica, Amirhossein Sahebkar. The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition. Expert Review of Clinical Pharmacology 2022; 15(10): 1199 doi: 10.1080/17512433.2022.2132229
|
| 16 |
Dario F. De Jesus, Tomohiko Kimura, Manoj K. Gupta, Rohit N. Kulkarni. NREP contributes to development of NAFLD by regulating one-carbon metabolism in primary human hepatocytes. Cell Chemical Biology 2023; 30(9): 1144 doi: 10.1016/j.chembiol.2023.06.001
|
| 17 |
Christy Foster, Charles A. Gagnon, Ambika P. Ashraf. Altered lipid metabolism and the development of metabolic-associated fatty liver disease. Current Opinion in Lipidology 2024; doi: 10.1097/MOL.0000000000000933
|
| 18 |
Anna Martin, Sonja Lang, Tobias Goeser, Münevver Demir, Hans-Michael Steffen, Philipp Kasper. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. Current Atherosclerosis Reports 2022; 24(7): 533 doi: 10.1007/s11883-022-01028-4
|